217 related articles for article (PubMed ID: 31620795)
1. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy.
Xie W; Xiao S; Huang Y; Sun X; Gao D; Ji L; Li G; Zhang Z
Rheumatology (Oxford); 2020 May; 59(5):930-939. PubMed ID: 31620795
[TBL] [Abstract][Full Text] [Related]
2. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
[TBL] [Abstract][Full Text] [Related]
3. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies.
Xie W; Yang X; Huang H; Gao D; Ji L; Zhang Z
Semin Arthritis Rheum; 2020 Oct; 50(5):930-937. PubMed ID: 32906027
[TBL] [Abstract][Full Text] [Related]
4. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
Strangfeld A; Hierse F; Rau R; Burmester GR; Krummel-Lorenz B; Demary W; Listing J; Zink A
Arthritis Res Ther; 2010; 12(1):R5. PubMed ID: 20064207
[TBL] [Abstract][Full Text] [Related]
5. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
[TBL] [Abstract][Full Text] [Related]
6. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
7. Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.
Baganz L; Listing J; Kekow J; Eisterhues C; Wassenberg S; Zink A; Strangfeld A
Semin Arthritis Rheum; 2020 Feb; 50(1):36-41. PubMed ID: 31350056
[TBL] [Abstract][Full Text] [Related]
8. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Singh S; Fumery M; Singh AG; Singh N; Prokop LJ; Dulai PS; Sandborn WJ; Curtis JR
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):561-576. PubMed ID: 30875456
[TBL] [Abstract][Full Text] [Related]
9. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence.
Singh N; Li CI
Curr Opin Rheumatol; 2021 May; 33(3):292-299. PubMed ID: 33741804
[TBL] [Abstract][Full Text] [Related]
10. Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data.
Jung SM; Kwok SK; Ju JH; Park YB; Park SH
Korean J Intern Med; 2019 May; 34(3):669-677. PubMed ID: 29172405
[TBL] [Abstract][Full Text] [Related]
11. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
12. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
14. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
[TBL] [Abstract][Full Text] [Related]
15. Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Bechman K; Halai K; Yates M; Norton S; Cope AP; ; Hyrich KL; Galloway JB
Arthritis Rheumatol; 2021 Oct; 73(10):1800-1809. PubMed ID: 33844458
[TBL] [Abstract][Full Text] [Related]
16. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
17. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
18. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
Mercer LK; Askling J; Raaschou P; Dixon WG; Dreyer L; Hetland ML; Strangfeld A; Zink A; Mariette X; Finckh A; Canhao H; Iannone F; Zavada J; Morel J; Gottenberg JE; Hyrich KL; Listing J
Ann Rheum Dis; 2017 Feb; 76(2):386-391. PubMed ID: 27307502
[TBL] [Abstract][Full Text] [Related]
19. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
Raaschou P; Frisell T; Askling J;
Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
[TBL] [Abstract][Full Text] [Related]
20. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.
Wadström H; Frisell T; Sparén P; Askling J;
Ann Rheum Dis; 2016 Jul; 75(7):1272-8. PubMed ID: 26755797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
